Drugs to Watch 2018
The year of the blockbuster

Download report

What is the report about?

Twelve new game-changing drugs are predicted to achieve annual sales of >$1 billion by 2022, to the benefit of millions of patients around the world.  Data for this report were compiled from Clarivate Analytics' Cortellis database, the premier source of life sciences competitive intelligence information and analytics.

Key findings

  • 12 new drugs entering the market in 2018 are anticipated to achieve blockbuster sales within 5 years
  • 2018 is a year with more potential blockbuster drug launches than any since launching the Drugs to Watch series in 2013
  • Despite uncertainties in the US and EU markets, the pace of pharmaceutical innovation continues to accelerate
  • Drugs on this list are valuable additions to existing treatments, disruptions to certain markets, and first-in-class treatment options for some indications

The drugs forecast to launch in 2018 cover a wide range of therapeutic areas, including:

  • Type 2 diabetes
  • Endometriosis
  • Childhood epilepsy
  • Hemophilia
  • HIV
  • Migraine
  • Opioid addiction
  • Shingles

Learn more

The annual Drugs to Watch report was first published in 2013. Using data from Cortellis, the report aims to forecast which drug launches in a given year will achieve blockbuster status within five years of launch. Following an advanced analysis of this database, a shortlist of drugs is manually researched and evaluated by life-science experts at Clarivate Analytics, who review each drug in its individual context and assess clinical trial results, regulatory data, market data and regulatory designations for each drug.

To learn more about the Cortellis suite of solutions for life science professionals, visit us at clarivate.com/cortellis. To find out more about Drugs to Watch, contact us.